FDA approves Lilly’s EBGLYSSยฎ for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
The U.S. FDA has approved a new maintenance dosing regimen for Eli…
Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer
Antag Therapeutics has appointed obesity treatment expert Philip Just Larsen as Chief…
Abu Dhabi Expands Access to Innovative Daily Oral Obesity Treatment
Abu Dhabi has expanded access to an innovative daily oral obesity treatment…
UAE: Emirates Drug Establishment approves oral obesity treatment
Emirates Drug Establishment, EDE UAE, orforglipron, Foundayo, Eli Lilly, oral obesity treatment,…
Saudi Arabia’s Riyadh to Host Landmark Life Sciences Summit in May 2026
Riyadh will host CPHI Middle East and BIO Middle East from May…
NVIDIA and Lilly Launch AI Co-Innovation Lab for Next-Generation Drug Discovery
NVIDIA and Lilly launch a $1 billion AI co-innovation lab in San…
Compliance Officer, Boehringer Ingelheim IMETA (India, Middle East, Turkey, Africa)
Hani Hussein is a seasoned compliance leader with over 25 years of…
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Eli Lilly and Company and Verve Therapeutics, Inc., a Boston-based clinical-stage company…
Lilly names Roberta Marinelli as new President & GM for Middle East & Tรผrkiye.
Lilly has appointed Roberta Marinelli as the President and General Manager for…
Lilly and EVA Pharma launch locally made Insulin in Egypt
December 2024- The Egyptian Drug Authority approved the insulin glargine injection manufactured…
